Publications
Want to collaborate?
Google Scholar
2024
Park J*, Wu J*, Szkop KJ, Jeong J, Husmann D, Flores NM, Francis JW, Chen YJ, Morales Benitez A, Zahn E, Song S, Ajani JA, Wang L, Singh L, Larsson O, Garcia BA, Topisirovic I, Gozani O*, Mazur PK*. SMYD5 methylation of rpL40 links ribosomal output to gastric cancer. Nature. 2024.
- Research Highlight (Cell Research): Lysine methylation steps into another step of the central dogma
- MD Anderson Research Highlights for August 21, 2024
- Featured Research (Nature Portfolio): Enzyme discovery heralds new target for gastric cancer treatment
Miao, B, Ge, L, He, C, Wang, X, Wu, J, Li, X, Chen, K, Wan, J, Xing, S, Ren, L, Shi, Z, Liu, S, Hu, Y, Chen, J, Yu, Y, Feng, L, Flores, NM*, Liang, Z, Xu, X, Wang, R, Zhou, J, Fan, J, Xiang, B, Li, E, Mao, Y, Cheng, J, Zhao, K, Mazur, PK*, Cai, J*, Lan, F*. SMYD5 is a ribosomal methyltransferase that catalyzes RPL40 lysine methylation to enhance translation output and promote hepatocellular carcinoma. Cell Res. 2024.
Cheng X, Dai E, Wu J, Flores NM, Chu Y, Wang R, Dang M, Xu Z, Han G, Liu Y, Chatterjee D, Hu C, Ying J, Du Y, Yang L, Guan X, Mo S, Cao X, Pei G, Jiang J, Lu X, Benitez AM, Waters RE, Pizzi MP, Shanbhag N, Fan Y, Peng F, Hanash SM, Calin G, Futreal A, Song S, Yee C, Mazur PK*, Qin JJ*, Ajani JA*, Wang L*. Atlas of Metastatic Gastric Cancer Links Ferroptosis to Disease Progression and Immunotherapy Response. Gastroenterology. 2024.
Francis JW, Hausmann S, Ikram S, Yin K, Mealey-Farr R, Flores NM, Trinh AT, Chasan T, Thompson J, Mazur PK*, Gozani O*. FAM86A methylation of eEF2 links mRNA translation elongation to tumorigenesis. Mol Cell. 2024.
Casanova AG, Roth GS, Hausmann S, Lu X, Belmudes L, Bourova-Flin E, Flores NM, Benitez AM, Caporicci M, Vayr J, Blanchet S, Ielasi F, Rousseaux S, Hainaut P, Gozani O, Couté Y, Palencia A, Mazur PK*, Reynoird N*. Cytoskeleton remodeling induced by SMYD2 methyltransferase drives breast cancer metastasis. Cell Discov. 2024.
- Genetic Engineering & Biotechnology News: Key Regulator of Breast Cancer Metastasis Unveiled
- MD Anderson Research Highlights for February 7, 2024
- Science & Vie (French): Cancer du sein: Une équipe Franco-/américaine identifie une protéine impliquée dans l’apparition de metastases
Fuentes ME, Lu X, Flores NM, Hausmann S, Mazur PK. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice. Sci Rep. 2024.
* corresponding authors
2023
Lu X, Lofgren SM, Zhao Y, Mazur PK. Multiplexed transcriptomic profiling of the fate of human CAR T cells in vivo via genetic barcoding with shielded small nucleotides. Nat Biomed Eng. 2023.
Fan Y, Li Y, Yao X, Jin J, Scott A, Liu B, Wang S, Huo L, Wang Y, Wang R, Pool Pizzi M, Ma L, Shao S, Sewastjanow-Silva M, Waters R, Chatterjee D, Liu B, Shanbhag N, Peng G, Calin GA, Mazur PK, Hanash SM, Ishizawa J, Hirata Y, Nagano O, Wang Z, Wang L, Xian W, McKeon F, Ajani JA, Song S. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment. Gut. 2023.
Gao G, Hausmann S, Flores NM, Benitez AM, Shen J, Yang X, Person MD, Gayatri S, Cheng D, Lu Y, Liu B, Mazur PK*, Bedford MT*. The NFIB/CARM1 partnership is a driver in preclinical models of small cell lung cancer. Nat Commun. 2023.
Mealey-Farr R, Jeong J, Park J, Liu S, Hausmann S, Francis JW, Angulo Ibanez M, Cho J, Chua K, Mazur PK, Gozani O*. Antibody toolkit to investigate eEF1A methylation dynamics in mRNA translation elongation. J Biol Chem. 2023.
Xu C, Huang KK, Law JH, Chua JS, Sheng T, Flores NM, Pizzi MP, Okabe A, Tan ALK, Zhu F, Kumar V, Lu X, Benitez AM, Lian BSX, Ma H, Ho SWT, Ramnarayanan K, Anene CG, Razavi M, Abdul SAB, Tay ST, Ong X, Lee MH, Guo YA, Ashktorab H, Smoot D, Li S, Skanderup AJ, Beer MA, Foo RSY, Wong JSH, Sanghvi K, Yong WP, Sundar R, Kaneda A, Prabhakar S, Mazur PK, Ajani JA, Yeoh KG, So JB, Tan P; Singapore Gastric Cancer Consortium. Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Gut. 2023.
Mello SS, Flowers BM, Mazur PK, Lee J, Mueller F, Denny S, Ferreira S, Hanson K, Kim S, Greenleaf W, Wood LD, Attardi LD. Multifaceted Role for p53 in Pancreatic Cancer Suppression. Proc Natl Acad Sci U S A. 2023.
* corresponding authors
2022
Lukinovic V, Hausmann S, Roth GS, Oyeniran C, Ahmad T, Tsao N, Brickner JR, Casanova AG, Chuffart F, Morales Benitez A, Vayr J, Rodell R, Tardif M, Jansen PWTC, Coute Y, Vermeulen M, Hainaut P, Mazur PK*, Mosammaparast N*, Reynoird N*. SMYD3 impedes small cell lung cancer sensitivity to alkylation damage through RNF113A methylation-phosphorylation crosstalk. Cancer Discov. 2022.
- MD Anderson Research Highlights for September 14, 2022
- Science Alert: Experimental Drug Treatment Stops A Deadly Form of Lung Cancer in Mice
- EurekAlert: Drug combo therapy in mice blocks drug resistance, halts tumor growth
- Daily Geek Show (French): Un traitement expérimental stoppe la croissance du cancer du poumon le plus agressif chez la souris
- New Atlas: Experimental drug combo halts growth of deadly lung cancer in mice
* corresponding authors
2021
Sengupta D, Zeng L, Li Y, Hausmann S, Ghosh D, Yuan G, Nguyen TN, Lyu R, Caporicci M, Bonitez Morales A, Coles GL, Kharchenko V, Czaban I, Azhibek D, Fischle W, Jaremko M, Wistuba II, Sage J, Jaremko L, Li W, Mazur PK*, Gozani O*. NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis. Mol Cell. 2021.
- MD Anderson Research Highlights for October 6, 2021
- EurekAlert: NSD2 epigenetic regulation cooperates with mutant KRAS to promote lung cancer
Hester R, Mazur PK, McAllister F. Immunotherapy in Pancreatic Adenocarcinoma: Beyond "Copy/Paste". Clin Cancer Res. 2021.
Yuan G, Flores NM, Hausmann S, Lofgren SM, Kharchenko V, Angulo-Ibanez M, Sengupta D, Lu X, Czaban I, Azhibek D, Vicent S, Fischle W, Jaremko M, Fang B, Wistuba II, Chua K, Roth JA, Minna JD, Shao NY, Jaremko L#, Mazur PK# and Gozani O#. Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature. 2021.
- Nature News & Views: An epigenetic tipping point in cancer comes under the microscope
- Nature Reviews: Drug Discovery: Squamous cell lung cancer changes driver
- Nature Reviews: Cancer: A driver gene hiding in plain sight
- Technology Networks: Mutant Enzyme Is a Main Driver of Lung Cancer
- EurekAlert: Enzymatic danse macabre of lung cancer
* corresponding authors
2020
Wang Z, Hausmann S, Lyu R, Li T, Lofgren SM, Flores NM, Fuentes ME, Caporicci M, Yang Z, Meiners M, Cheek M, Howard S, Zhang L, Elias JE, Kim MP, Maitra A, Wang H, Bassik M, Keogh M, Sage J, Gozani O#, Mazur PK#. SETD5-coordinated chromatin reprogramming regulates adaptive resistance to targeted pancreatic cancer therapy. Cancer Cell. 2020.
Valencia K, Erice O, Kostyrko K, Hausmann S, Guruceaga E, Tathireddy A, Flores NM, Sayles LC, Lee AG, Fragoso R, Sun TQ, Vallejo A, Roman M, Entrialgo-Cadierno R, Migueliz I, Razquin N, Fortes P, Lecanda F, Lu J, Ponz M, Chen CZ, Mazur PK#, Sweet-Cordero EA#, Vicent S#. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas. J Clin Invest. 2020.
# corresponding authors
2019
Liu S*, Hausmann S*, Carlson SM, Fuentes ME, Francis JW, Pillai R, Lofgren SM, Hulea L, Tandoc K, Lu J, Li A, Nguyen ND, Caporicci M, Kim MP, Maitra A, Wang H, Wistuba II, Porco JA Jr, Bassik MC, Elias JE, Song J, Topisirovic I, Van Rechem C, Mazur PK#, Gozani O#. METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis. Cell. 2019.
- Cancer Discovery: KRAS-Driven Cancers Are Dependent on METTL13-Mediated eEF1A Methylation
- Current Protein & Peptide Science: Lysine methyltransferases signaling: Histones are just the tip of the iceberg
* contributed equally
# corresponding authors
2017
Mello SS, Sinow C, Raj N, Mazur PK, Bieging-Rolett K, Broz DK, Imam JFC, Vogel H, Wood LD, Sage J, Hirose T, Nakagawa S, Rinn J, Attardi LD. Neat1 is a p53-inducible lincRNA essential for transformation suppression. Genes Dev. 2017.
Vallejo A, Perurena N, Guruceaga E, Mazur PK, Martinez-Canarias S, Zandueta C, Valencia K, Arricibita A, Gwinn D, Sayles LC, Chuang CH, Guembe L, Bailey P, Chang DK, Biankin A, Ponz-Sarvise M, Andersen JB, Khatri P, Bozec A, Sweet-Cordero EA, Sage J, Lecanda F, Vicent S. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nat Commun. 2017.
2016
Jahchan NS, Lim JS, Bola B, Morris K, Seitz G, Tran KQ, Xu L, Trapani F, Morrow CJ, Cristea S, Coles GL, Yang D, Vaka D, Kareta MS, George J, Mazur PK, Nguyen T, Anderson WC, Dylla SJ, Blackhall F, Peifer M, Dive C, Sage J. Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. Cell Reports. 2016.
Krampitz GW, George BM, Willingham SB, Volkmer JP, Weiskopf K, Jahchan N,Newman AM, Sahoo D, Zemek AJ, Yanovsky RL, Nguyen JK, Schnorr PJ, Mazur PK, Sage J, Longacre TA, Visser BC, Poultsides GA, Norton JA, Weissman IL. Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A. 2016.
Reynoird N*, Mazur PK*, Stellfeld T, Flores NM, Lofgren SM, Carlson SM,Brambilla E, Hainaut P, Kaznowska EB, Arrowsmith CH, Khatri P, Stresemann C,Gozani O, Sage J. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer. Genes Dev. 2016.
* equally contributed
2015
Mazur PK*#, Herner A*, Mello SS, Wirth M, Hausmann S, Sánchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D, Trajkovic-Arsic M, Gupta A, Heid I, Noël PB, Braren R, Erkan M, Kleeff J, Sipos B, Sayles LC, Heikenwalder M, Heßmann E, Ellenrieder V, Esposito I, Jacks T, Bradner JE, Khatri P, Sweet-Cordero EA, Attardi LD, Schmid RM, Schneider G, Sage J#, Siveke J#. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med. 2015.
* contributed significantly
# co-coresponding authors
2014
Mazur PK*, Reynoird N*, Khatri P, Jansen PW, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, Tummino PJ, Kruger RG, Garcia BA, Butte AJ, Vermeulen M, Sage J, Gozani O. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 2014.
Baumgart A*, Mazur PK*, Anton M, Rudelius M, Schwamborn K, Feuchtinger A, Behnke K, Walch A, Braren R, Peschel C, Duyster J, Siveke JT, Dechow T. Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model. Oncogene. 2014.
Chen R, Khatri P*, Mazur PK*, Polin M, Zheng Y, Vaka D, Hoang CD, Shrager J, Xu Y, Vicent S, Butte AJ, Sweet-Cordero EA. A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma. Cancer Res. 2014.
* equally contributed
2013
Jameson KL*, Mazur PK*, Zehnder AM, Zhang J, Zarnegar B, Sage J, Khavari PA. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAPK-driven tumors. Nat Med. 2013.
Jahchan NS, Dudley JT*, Mazur PK*, Flores N, Yang D, Palmerton A, Zmoos AF, Vaka D, Tran KQ, Zhou M, Krasinska K, Riess JW, Neal JW, Khatri P, Park KS, Butte AJ, Sage J. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 2013.
* equally contributed
2012
Ardito CM, Grüner BM, Takeuchi KK, Lubeseder C, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, Pal D, Briel T, Herner A, Trajkovic-Arsic M, Sipos B, Liou GY, Storz P, Murray NR, Threadgill DW, Sibilia M, Washington MK, Wilson CL, Schmid RM, Raines EW, Crawford HC, Siveke JT. EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis. Cancer Cell. 2012.
Grüner BM, Hahne H, Mazur PK, Trajkovic-Arsic M, Maier S, Esposito I, Kalideris E, Michalski CW, Kleeff J, Rauser S, Schmid RM, Küster B, Walch A, Siveke JT. MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer. PLoS One. 2012.
Aichler M, Seiler C, Tost M, Siveke J, Mazur PK, Da Silva-Buttkus P, Bartsch DK, Langer P, Chiblak S, Dürr A, Höfler H, Klöppel G, Müller-Decker K, Brielmeier M, Esposito I. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J Pathol. 2012.
2011
Mazur PK, Riener MO, Jochum W, Kristiansen G, Weber A, Schmid RM, Siveke JT. Expression and Clinicopathological Significance of Notch Signaling and Cell-Fate Genes in Biliary Tract Cancer. Gastroenterology. 2011.
Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, Zmoos AF, Mazur PK, Schaffer BE, Ostermeier A, Vogel H, Sylvester KG, Thorgeirsson SS, Grompe M, Sage J. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med. 2011.
Heid I, Lubeseder C, Sipos B, Mazur PK, Lesina M, Schmid RM, Siveke JT. Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology. 2011.
2010
Mazur PK, Einwächter H, Lee M, Sipos B, Nakhai H, Rad R, Zimber-Strobl U, Strobl LJ, Radtke F, Klöppel G, Schmid RM, Siveke JT. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2010.
Mazur PK, Grüner BM, Nakhai H, Sipos B, Zimber-Strobl U, Strobl LJ, Radtke F, Schmid RM, Siveke JT. Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in murine Kras(G12D)-induced skin carcinogenesis in vivo. PLoS One. 2010.
2008
Geisler F, Nagl F, Mazur PK, Lee M, Zimber-Strobl U, Strobl LJ, Radtke F, Schmid RM, Siveke JT. Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice. Hepatology. 2008.
Nakhai H, Siveke JT, Klein B, Mazur PK, Algül H, Radtke F, Strobl L, Zimber-Strobl U, Schmid RM. Conditional ablation of Notch signaling in pancreatic development. Development. 2008.
Siveke JT, Lubeseder-Martellato C, Lee M, Mazur PK, Nakhai H, Radtke F, Schmid RM. Notch signaling is required for exocrine regeneration after acute pancreatitis. Gastroenterology. 2008.
Selected Reviews
Mazur PK, Sage J. Pancreatic cancer takes its Toll. J Exp Med. 2015.
Mazur PK, Neff F, Herner A, Siveke JT. Current Methods in Mouse Models of Pancreatic Cancer, Methods in Molecular Biology volume on Mouse Models of Cancer, Humana Press (book chapter), 2015.
Mazur PK, Siveke JT. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Gut. 2012.
Jagielski T, van Ingen J, Rastogi N, Dziadek J, Mazur PK, Bielecki J. Current methods in the molecular typing of Mycobacterium tuberculosis and other mycobacteria. Biomed Res Int. 2005.